Recent 8-K filings for NTRA

• August 6, 2026, 4:05 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Natera Q2 revenue $752.8M (+37.7% YoY); raises FY2026 guidance by $100M

  Revenue $752.8M (+37.7% YoY); tests processed 1,043,900 (+22.4%); oncology tests 296,700 (+57.2%).

• May 7, 2026, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q1 revenue $696.6M (+39% YoY); raises FY2026 guidance by $120M to $2.78B midpt

  Revenue $696.6M (+38.8% YoY); tests processed 1,013,600 (+18.5%), oncology tests up 54.4%.

• February 26, 2026, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera Q4 2025 revenue $665.5M (+39.8% YoY); guides FY26 revenue $2.62-2.70B

  Revenue $665.5M Q4 2025 vs $476.1M Q4 2024 (+39.8%); FY2025 revenue $2,306.1M (+35.9%).

• January 12, 2026, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Natera preliminary Q4 rev ~$660M (+39% YoY), FY rev ~$2.3B (+35%), above outlook

  Q4 total revenue ~$660M (+39% YoY); FY 2025 ~$2.3B (+35%), ~$40M above top end of prior outlook.

• December 5, 2025, 6:59 PM ET M&A materiality 0.80 positive item 3.02item 8.01item 9.01

  Natera acquires Foresight Diagnostics for $275M upfront plus $175M earnouts

  All-stock acquisition includes $275M upfront consideration plus up to $175M in revenue- and reimbursement-based milestone earnouts.

• November 6, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera Q3 revenue up 35% to $592M; raises FY2025 guidance by $160M midpoint

  Revenue $592.2M (+34.7% YoY); product rev +35.3%; gross margin 64.9% vs 61.8%.

• August 7, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Natera Q2 revenue up 32% to $546.6M; raises FY2025 revenue outlook by $80M

  Total revenue $546.6M (+32.2% YoY); product revenue $544.4M (+32.3%).

• May 8, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Natera Q1 revenue $501.8M (+36.5% YoY); positive cash flow $23.2M

  Total revenue $501.8M (+36.5% YoY); product revenue $500.0M (+37.1%).

• February 27, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera Q4 revenue $476M (+53% YoY); guides 2025 revenue $1.87-1.95B

  Q4 total revenue $476.1M (+53% YoY); product revenue $472.9M (+53.9%).

• January 13, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera FY2024 preliminary revenue ~$1.7B (+56% YoY), positive cash inflow $86.3M

  Q4 2024 revenue ~$472M (+52% YoY); FY2024 revenue ~$1.7B (+56% YoY), ~$53M above top end of guidance.

• December 6, 2024, 6:59 PM ET leadership materiality 0.60 neutral item 5.02

  Natera amends employment agreement for Executive Chairman Matthew Rabinowitz

  Rabinowitz's base salary set at 50% of CEO's base salary, with annual cash bonus up to 85% of base salary.

• November 12, 2024, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Natera Q3 revenue $439.8M (+64% YoY), beats guidance; raises FY2024 forecast

  Revenue $439.8M (+63.9% YoY); product revenue up 64.4%; gross margin 61.8% vs 45.1%.

• August 8, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Natera Q2 revenue up 58% to $413.4M, loss narrows to $37.5M, guides higher

  Revenue $413.4M (+58.1% YoY); product revenue $411.4M (+59.3%); gross margin 58.8% vs 45.2%.

• July 22, 2024, 7:59 PM ET debt materiality 0.60 neutral item 8.01

  Natera to redeem all $287.5M of 2.25% Convertible Notes due 2027 on Oct 11

  Natera elects to redeem all $287.5M aggregate principal of its 2.25% Convertible Senior Notes due 2027.

• May 9, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q1 revenue $367.7M (+52% YoY), net loss narrows to $0.56/share; achieves positive cash flow

  Revenue $367.7M (+52.1% YoY); product revenue up 53.4%; gross margin 56.7% vs 38.7%.

• February 28, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q4 revenue up 43% to $311M; net loss narrows; guides 2024 rev $1.32-1.35B

  Q4 revenue $311.1M (+43.2% YoY); product revenue up 44.3% to $307.3M.

• January 22, 2024, 6:59 PM ET M&A materiality 0.65 positive item 8.01item 9.01

  Natera acquires Invitae's prenatal and carrier screening assets for $10M upfront

  Upfront cash payment of $10 million to Invitae for reproductive health assets.

• January 9, 2024, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera prelim Q4 revenue ~$300M (+38% YoY); FY23 ~$1.07B (+30%), $20M above guidance

  Q4 2023 revenue approx. $300M, up 38% from $217M in Q4 2022.

• November 8, 2023, 6:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q3 revenue $268.3M (+27% YoY), raises FY2023 revenue and margin guidance, reduces cash burn

  Revenue $268.3M, up 27% YoY; product revenue $265.2M, up 33% YoY.

• September 7, 2023, 7:59 PM ET other material materiality 0.65 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Natera prices $250M follow-on offering of 4.55M shares at $55; net proceeds ~$235.4M

  Priced 4,550,000 shares of common stock at $55.00 per share; underwriters granted 30-day option for 682,500 additional shares.

• August 3, 2023, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q2 revenue $261.4M (+31.9% YoY); net loss narrows; raises FY 2023 guidance

  Total revenue $261.4M, up 31.9% YoY; product revenue $258.3M (+32.7%).

• May 9, 2023, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q1 revenue $241.8M (+24.5% YoY), raises 2023 revenue guidance to $995M-$1.015B

  Total revenue $241.8M (+24.5% YoY); product revenue $237.8M (+25.2% YoY).

• March 13, 2023, 7:59 PM ET other material materiality 0.70 positive item 7.01

  Natera discloses no exposure to Silicon Valley Bank

  No cash deposits or securities held at Silicon Valley Bank as of March 10, 2023.

• February 28, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Natera Q4 revenue $217.3M (+25.6% YoY); net loss $142.6M; guides 2023 rev $980M-$1B

  Q4 total revenue $217.3M (+25.6% YoY); product revenue $212.9M (+28.2%); tests processed 559,700 (+27.6%).

• November 16, 2022, 6:59 PM ET other material materiality 0.75 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Natera prices $400M follow-on offering of 11.43M shares at $35/share

  Priced 11,430,000 shares at $35.00 per share, with underwriters' option for 1,714,500 additional shares.

• November 8, 2022, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01 ◈ Earnings Releases

  Natera Q3 revenue $210.6M (+33% YoY), raises FY22 guidance to $810M-$830M

  Total revenues $210.6M, up 33% YoY; test volumes 517,500 (+27% YoY).

• August 4, 2022, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01

  Natera Q2 revenue up 40% to $198.2M; raises FY2022 guidance to $805M-$825M

  Total revenue $198.2M (+39.6% YoY); product revenue $194.6M (+39.3%).

• May 5, 2022, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Natera Q1 revenue $194.1M (+27.5% YoY), raises 2022 guidance to $790-810M

  Product revenue $190M, up 57.8% YoY; processed 489,300 tests, up 40.5%.

• March 14, 2022, 7:59 PM ET other material materiality 0.60 positive item 5.02item 9.01

  Natera executives and board to take stock instead of cash salaries and retainers for 2022

  Executives receive RSUs: CEO Chapman 13,708, CFO Brophy 9,108, COO Schueren 9,634, Sheena 4,141, Rabinowitz 6,763; vest Dec 31, 2022.

• February 24, 2022, 6:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01

  Natera Q4 revenue $173M (+54% YoY); net loss widens to $140.6M; FY 2022 guidance $770-790M

  Q4 2021 revenue $173.0M (+53.9% YoY); full year 2021 revenue $625.5M (+60% YoY), exceeding prior guidance.

• November 4, 2021, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Natera Q3 revenue $158.1M (+61% YoY), net loss $151.3M; raises FY2021 revenue guidance

  Revenue $158.1M (+61.1% YoY); product revenue $150.7M (+61.5%); tests processed 407,300 (+55.4%).

• August 5, 2021, 7:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01

  Natera Q2 revenue up 64% to $142M; guides FY2021 revenue to $600-620M

  Product revenue $137.2M, +70.7% YoY; processed 375,700 tests, +60.5%.

• July 22, 2021, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Natera prices follow-on offering of 4.5M shares at $113/share, expects ~$478.8M net proceeds

  Offering of 4,500,000 shares at $113.00 per share; closing expected July 26, 2021.

• July 20, 2021, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 8.01item 9.01

  Natera reports preliminary Q2 revenue ~$138-141M (+60% YoY); Women's Health cash flow breakeven

  Total revenue expected $138-141M vs $86.5M in Q2 2020, a record ~60% YoY growth.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.72 · Most common event earnings

24 positive 1 negative 23 neutral

source · NTRA on sec.gov